Act A - The Market Structure
A modern biological deep-freezer is a multi-million-dollar black box. Thousands of tubes of specialized antibodies, RNA extractions, and unique cell lines sit unused as researchers move on to new projects. Because there is no inter-university visibility, the default action is to order fresh supply from commercial vendors. When supply chains shock or items go on backorder, vital, time-sensitive research simply halts.
Act B - The Story
Dr. Evans is conducting a critical study on leukemia, but a highly specific, $4,000 signaling antibody is globally backordered for six months. Her grant timeline doesn't have six months to spare.
Dr. Tremblay at McGill concluded a similar study a year ago and has three unopened vials of that exact antibody sitting in a -80C freezer, deprecating toward expiry.
Dr. Evans posts her need on the academic exchange platform. The system queries the aggregated metadata of participating university freezers and flags Dr. Tremblay's surplus. Crucially, the platform automatically generates a non-commercial Material Transfer Agreement (MTA) verifying that Dr. Evans's ethics approval covers her use of the reagent. Both PIs digitally sign. The platform dispatches a specialized dry-ice courier to McGill, and the antibody arrives in Halifax 24 hours later.
Act C - Why This Market Stays Broken Without Infrastructure
Without algorithmic matching and integrated legal frameworks, sharing reagents relies on serendipitous conversations at conferences. DeeperPoint turns siloed academic freezers into a unified, resilient national supply chain, saving millions in wasted grant funding and accelerating scientific discovery.
Characters are fictional. Academic supply chain bottlenecks are real. DeeperPoint is building the infrastructure this story describes.